Galectin Therapeutics — Q3 2026 Earnings Summary
Financial Performance:
- Reported net loss applicable to common stockholders of $3.6 million ($0.04 per share) for the quarter ended September 30, 2026, compared to $8.2 million ($0.13 per share) for the quarter ended June 30, 2025.
- Research and development expenses were $1.6 million for the quarter ended September 30, 2026, down from $2.6 million in the same period in 2025, primarily due to timing of expenditures related to the NAVIGATE clinical trial.
- General and administrative expenses were $1.8 million for the quarter ended September 30, 2026, up from $1.6 million in the quarter ended September 30, 2025, driven by increased non-cash stock-based compensation.
- Cash and cash equivalents stood at $11.7 million as of September 30, 2026, down from $17.7 million as of December 31, 2025.
- Total liabilities decreased to $46.4 million as of September 30, 2026, from $145.7 million as of December 31, 2025.
- Total stockholders' deficit improved to $(35.2) million as of September 30, 2026, compared to $(127.9) million as of December 31, 2025.
- Interest expense for the quarter ended September 30, 2026, was $0.8 million, a significant decrease from $1.8 million in the same period in 2025.
- Change in fair value of derivative liabilities resulted in a gain of $0.6 million for the quarter ended September 30, 2026, compared to a loss of $2.2 million in the same period in 2025.
Guidance and Future Outlook:
- The Company believes it has sufficient cash to fund currently planned operations and research and development activities through June 2027.
- Additional information regarding the Phase 3 trial design is expected to be presented at the Annual Stockholders' Meeting on December 3, 2026.
- The registrational Phase 3 trial protocol for belapectin in advanced MASH cirrhosis with portal hypertension was filed with the FDA in the third quarter of 2026.
- Alignment was reached with the FDA on key elements of the planned Phase 3 trial design, including the primary endpoint of composite liver outcome, blinded central review for esophageal varices, and a single 2 mg/kg LBM dose of belapectin.
Business Segments and Product Lines:
- Belapectin, a complex carbohydrate drug targeting galectin-3, is the lead program for Metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.
- At the AASLD Annual Meeting, new analyses from the global NAVIGATE Phase 2b/3 trial were presented, showing belapectin treatment associated with a favorable shift toward lower ANTICIPATE-NASH predicted clinically significant portal hypertension (CSPH) risk at 18 months, with a net 15.9% placebo-adjusted improvement (p=0.04).
- Variceal incidence was consistently lower in patients treated with belapectin versus placebo across all baseline risk categories in the NAVIGATE trial.
- A "Poster of Distinction" highlighted that Baveno VII criteria and ELF score enable risk stratification for CSPH and risk of decompensation, respectively, in the NAVIGATE trial.
- Analysis of the Phase 2b GT-026 trial showed that Baveno VII demonstrated slightly better concordance and broader risk stratification than ANTICIPATE-NASH when compared to HVPG-defined CSPH.
- Additional development programs include combination immunotherapy for advanced head and neck cancers and other malignancies, with advancement largely dependent on finding a suitable partner.
Market and Competitive Landscape:
- Galectin Therapeutics holds Fast Track designation by the U.S. Food and Drug Administration for belapectin.
- The Company presented data at AASLD for the fourth consecutive major liver conference, with data included in conference highlights and the portal hypertension debrief.
- Liver cirrhosis is identified as one of the most pressing medical needs and a significant drug development opportunity.
Risks and Challenges:
- Forward-looking statements indicate that full analysis of NAVIGATE trial data may not produce positive results.
- There is no guarantee of successful development of effective treatments or obtaining requisite approvals for belapectin or other drugs.
- Risks include potential difficulties in scaling up manufacturing and meeting chemistry, manufacturing, and control requirements.
- Clinical trials may not produce positive results in a timely fashion, could require larger and longer trials, and may be time-consuming and costly.
- The Company has incurred operating losses since inception and its ability to develop and market drugs may be impacted by its ability to manage costs and finance continuing operations.
- Success is dependent on finding suitable partners for additional clinical programs and raising additional capital.
Management Commentary and Tone:
- CEO Joel Lewis expressed extreme pleasure with the positive feedback received on oral and poster presentations at AASLD and excitement regarding data inclusion in conference highlights.
- Management highlighted the simplification of the capital structure and strengthening of the balance sheet following the conversion of debt to equity.
- The tone reflects confidence in the alignment with the FDA and the potential utility of noninvasive tools like ANTICIPATE-NASH and Baveno VII for enriching clinical trial populations.
Other Key Points:
- Chairman Richard E. Uihlein converted all outstanding principal and accrued interest under five of the Company's line of credit facilities into 34,376,167 shares of common stock effective July 31, 2026.
- The conversion transaction eliminated approximately $105.8 million in total debt, consisting of $91.0 million in principal and $14.8 million in accrued interest.
- One credit facility (December 2025) remains undrawn and available, with $10 million remaining available under the line of credit provided by the Chairman.
- The transaction covers all notes under five of six credit facilities.
- The Company's Quarterly Report on Form 10-Q for the period ended September 30, 2026, has been filed with the SEC.
- Company
- GALECTIN THERAPEUTICS INC
- Sector
- Healthcare
- Industry
- Biotechnology